Kate Means is the vice president of Operations, Third-Party Logistics for RxCrossroads by McKesson. Kate joined McKesson in 2019 with over 20 years of experience in global supply chain and logistics specializing in transitioning businesses and leading teams to achieve sustainable excellence. She is currently responsible for the daily operational performance and strategic development of third-party logistic services for pharmaceutical manufacturers, creating solutions tailored for each client’s specific needs. In this role, she leads operational teams that are the silent partner for manufacturers big or small, established or launching, to provide the optimal representation of their brand and patient experience. Kate graduated with a BS in business administration from the Whittemore School of Business at the University of New Hampshire.
March 16, 2020
While the cell and gene therapies approved so far are indicated for rare diseases with small patient populations, the successes of chimeric antigen receptor-T (CAR-T) therapies and expanding interest from biopharma stress the need to rapidly scale the supply chain as these therapies move toward commercial availability for more disease states and larger patient populations.